Organization
Pfizer Inc, Groton, CT, United States of America
4 abstracts
Abstract
AGE-BASED (<65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIESOrg: Pfizer Inc, Montreal, QC, Canada, Pfizer Inc, Sollentuna, Sweden, Pfizer Inc, Groton, CT, United States of America, Pfizer Inc, Peapack, NJ, United States of America, Pfizer Inc, Collegeville, PA, United States of America,
Abstract
An integrated analysis of changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis across phase 3 and long-term extension studiesOrg: Pfizer Inc, Groton, CT, United States of America, Pfizer Inc, Collegeville, PA, USA,
Abstract
ANALYSIS OF NON-MELANOMA SKIN CANCER ACROSS THE TOFACITINIB RHEUMATOID ARTHRITIS CLINICAL PROGRAMME Org: University of Alabama, Birmingham, United States, Seoul National University, Seoul, Korea, Republic Of, Dermatology and Laser Center of Maui, Maui, United States, University of Paris-Sud, Paris, France, Pfizer Inc, Groton, CT, United States of America,
Abstract
BASELINE PAIN SEVERITY AS A PREDICTOR OF PAIN IMPROVEMENT FOLLOWING TREATMENT WITH TOFACITINIB IN PSORIATIC ARTHRITISOrg: Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States of america, UZ Leuven, Leuven, Belgium, Pfizer Inc, Groton, CT, United States of America, Swedish Medical Center and University of Washington, Seattle, WA, United States of america, Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, United States of america,